Cargando…

Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12–17 Years in the United States

As part of a phase 4, randomized, double-blind, placebo-controlled trial to assess the immunogenicity and safety of PXVX0200 in children and adolescents aged 2–17 years, a subset of 73 adolescent subjects aged 12–17 years was followed for 2 years after vaccination and had blood collected for antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: McCarty, James M., Cassie, David, Bedell, Lisa, Lock, Michael D., Bennett, Sean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Tropical Medicine and Hygiene 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103473/
https://www.ncbi.nlm.nih.gov/pubmed/33819178
http://dx.doi.org/10.4269/ajtmh.20-1576
_version_ 1783689314515812352
author McCarty, James M.
Cassie, David
Bedell, Lisa
Lock, Michael D.
Bennett, Sean
author_facet McCarty, James M.
Cassie, David
Bedell, Lisa
Lock, Michael D.
Bennett, Sean
author_sort McCarty, James M.
collection PubMed
description As part of a phase 4, randomized, double-blind, placebo-controlled trial to assess the immunogenicity and safety of PXVX0200 in children and adolescents aged 2–17 years, a subset of 73 adolescent subjects aged 12–17 years was followed for 2 years after vaccination and had blood collected for antibody assays on days 1, 11, 29, 91, 181, 365, 547, and 730. Endpoints included serum vibriocidal antibody (SVA) seroconversion, defined as a 4-fold or greater rise in antibody titer over baseline; geometric mean titers (GMTs); and geometric mean fold increase (GMFI) over baseline. Serum vibriocidal antibody seroconversion persisted in most subjects, with a rate of 64.5% noted at day 730. Geometric mean titers and GMFI both peaked at day 11 and remained greater than baseline at all time points, including day 730. Vaccination with PXVX0200 produces an immune response which persists for at least 2 years in adolescents aged 12–17 years.
format Online
Article
Text
id pubmed-8103473
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The American Society of Tropical Medicine and Hygiene
record_format MEDLINE/PubMed
spelling pubmed-81034732021-05-10 Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12–17 Years in the United States McCarty, James M. Cassie, David Bedell, Lisa Lock, Michael D. Bennett, Sean Am J Trop Med Hyg Articles As part of a phase 4, randomized, double-blind, placebo-controlled trial to assess the immunogenicity and safety of PXVX0200 in children and adolescents aged 2–17 years, a subset of 73 adolescent subjects aged 12–17 years was followed for 2 years after vaccination and had blood collected for antibody assays on days 1, 11, 29, 91, 181, 365, 547, and 730. Endpoints included serum vibriocidal antibody (SVA) seroconversion, defined as a 4-fold or greater rise in antibody titer over baseline; geometric mean titers (GMTs); and geometric mean fold increase (GMFI) over baseline. Serum vibriocidal antibody seroconversion persisted in most subjects, with a rate of 64.5% noted at day 730. Geometric mean titers and GMFI both peaked at day 11 and remained greater than baseline at all time points, including day 730. Vaccination with PXVX0200 produces an immune response which persists for at least 2 years in adolescents aged 12–17 years. The American Society of Tropical Medicine and Hygiene 2021-05 2021-04-05 /pmc/articles/PMC8103473/ /pubmed/33819178 http://dx.doi.org/10.4269/ajtmh.20-1576 Text en © The American Society of Tropical Medicine and Hygiene https://creativecommons.org/licenses/by-nc/4.0/Open Access statement. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and reproduction in any medium for non-commercial purposes, provided the original author and source are credited, a link to the CC License is provided, and changes – if any – are indicated.
spellingShingle Articles
McCarty, James M.
Cassie, David
Bedell, Lisa
Lock, Michael D.
Bennett, Sean
Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12–17 Years in the United States
title Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12–17 Years in the United States
title_full Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12–17 Years in the United States
title_fullStr Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12–17 Years in the United States
title_full_unstemmed Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12–17 Years in the United States
title_short Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12–17 Years in the United States
title_sort long-term immunogenicity of live oral cholera vaccine cvd 103-hgr in adolescents aged 12–17 years in the united states
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103473/
https://www.ncbi.nlm.nih.gov/pubmed/33819178
http://dx.doi.org/10.4269/ajtmh.20-1576
work_keys_str_mv AT mccartyjamesm longtermimmunogenicityofliveoralcholeravaccinecvd103hgrinadolescentsaged1217yearsintheunitedstates
AT cassiedavid longtermimmunogenicityofliveoralcholeravaccinecvd103hgrinadolescentsaged1217yearsintheunitedstates
AT bedelllisa longtermimmunogenicityofliveoralcholeravaccinecvd103hgrinadolescentsaged1217yearsintheunitedstates
AT lockmichaeld longtermimmunogenicityofliveoralcholeravaccinecvd103hgrinadolescentsaged1217yearsintheunitedstates
AT bennettsean longtermimmunogenicityofliveoralcholeravaccinecvd103hgrinadolescentsaged1217yearsintheunitedstates